Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025
Heron Therapeutics (HRTX) has announced it will host a conference call and live webcast on Tuesday, May 6, 2025, at 8:00 a.m. ET to discuss its first quarter 2025 financial results and recent business highlights.
Participants are encouraged to dial in fifteen minutes before the scheduled start time to avoid delays. The event will be accessible via phone through a registration link and webcast through the Investor Relations section of Heron's website. A recording will be available on the company's website for 60 days following the call.
Heron Therapeutics (HRTX) ha annunciato che terr脿 una conference call e una diretta web marted矛 6 maggio 2025 alle 8:00 ET per discutere i risultati finanziari del primo trimestre 2025 e gli ultimi aggiornamenti aziendali.
Si consiglia ai partecipanti di collegarsi quindici minuti prima dell'orario previsto per evitare ritardi. L'evento sar脿 accessibile telefonicamente tramite un link di registrazione e in diretta streaming nella sezione Investor Relations del sito web di Heron. Una registrazione sar脿 disponibile sul sito dell'azienda per 60 giorni dopo la chiamata.
Heron Therapeutics (HRTX) ha anunciado que realizar谩 una llamada conferencia y una transmisi贸n en vivo el martes 6 de mayo de 2025 a las 8:00 a.m. ET para discutir los resultados financieros del primer trimestre de 2025 y las novedades recientes del negocio.
Se recomienda a los participantes conectarse quince minutos antes de la hora programada para evitar retrasos. El evento ser谩 accesible por tel茅fono mediante un enlace de registro y por webcast a trav茅s de la secci贸n de Relaciones con Inversores en el sitio web de Heron. Una grabaci贸n estar谩 disponible en el sitio web de la compa帽铆a durante 60 d铆as despu茅s de la llamada.
Heron Therapeutics (HRTX)電� 2025雲� 5鞗� 6鞚� 頇旍殧鞚� 鞓れ爠 8鞁�(霃欕秬鞁滉皠)鞐� 2025雲� 1攵勱赴 鞛 瓴瓣臣 氚� 斓滉芳 靷梾 順勴櫓鞚� 雲检潣頃橁赴 鞙勴暅 旎嵓霟办姢 旖滉臣 霛检澊敫� 鞗轨簮鞀ろ姼毳� 臧滌禍頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟.
彀胳劃鞛愲姅 歆�鞐办潉 氚╈頃橁赴 鞙勴暣 鞓堨爼 鞁滉皠 15攵� 鞝勳棎 鞝戩啀頃� 瓴冹潉 甓岇灔頃╇媹雼�. 頄夓偓電� 霌彪 毵來伂毳� 韱淀暅 鞝勴檾 鞝戩啀瓿� Heron 鞗轨偓鞚错姼鞚� 韴瀽鞛� 甏�瓿� 靹轨厴鞚� 韱淀暅 鞗轨簮鞀ろ姼搿� 彀胳棳頃� 靾� 鞛堨姷雼堧嫟. 韱淀檾 頉� 60鞚缄皠 須岇偓 鞗轨偓鞚错姼鞐� 雲鬼檾氤胳澊 鞝滉车霅╇媹雼�.
Heron Therapeutics (HRTX) a annonc茅 qu'elle tiendra une conf茅rence t茅l茅phonique et une diffusion en direct le mardi 6 mai 2025 脿 8h00 ET pour discuter des r茅sultats financiers du premier trimestre 2025 et des faits marquants r茅cents de l'entreprise.
Les participants sont invit茅s 脿 se connecter quinze minutes avant l'heure pr茅vue afin d'茅viter tout retard. L'茅v茅nement sera accessible par t茅l茅phone via un lien d'inscription et en webcast dans la section Relations Investisseurs du site web de Heron. Un enregistrement sera disponible sur le site de la soci茅t茅 pendant 60 jours apr猫s l'appel.
Heron Therapeutics (HRTX) hat angek眉ndigt, am Dienstag, den 6. Mai 2025, um 8:00 Uhr ET eine Telefonkonferenz und einen Live-Webcast abzuhalten, um die Finanzergebnisse des ersten Quartals 2025 und aktuelle Gesch盲ftshighlights zu besprechen.
Teilnehmer werden gebeten, sich f眉nfzehn Minuten vor Beginn einzuw盲hlen, um Verz枚gerungen zu vermeiden. Die Veranstaltung ist telefonisch 眉ber einen Registrierungslink und per Webcast im Bereich Investor Relations auf der Website von Heron zug盲nglich. Eine Aufzeichnung wird f眉r 60 Tage nach dem Anruf auf der Unternehmenswebsite verf眉gbar sein.
- None.
- None.
The conference call can be accessed by phone by utilizing the following聽聽which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Investor Relations section of Heron's website at聽www.herontx.com. An archive of the teleconference and webcast will also be made available on Heron's website for 60 days following the call.
About聽Heron Therapeutics, Inc.
Heron Therapeutics, Inc.聽is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit聽.
Forward-looking Statements
This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company's filings with the聽Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.
Investor Relations and Media Contact:
Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
[email protected]
858-251-4400
View original content to download multimedia:
SOURCE Heron Therapeutics, Inc.
FAQ
When will Heron Therapeutics (HRTX) report Q1 2025 earnings?
How can investors access Heron Therapeutics' Q1 2025 earnings call?
How long will Heron Therapeutics' Q1 2025 earnings call recording be available?
What time should participants join HRTX's Q1 2025 earnings call?
